Pneumothorax with MCC DRG Reimbursement & Medicare

DRG 199 addresses inpatient admissions for pneumothorax with Major Complication or Comorbidity, covering cases with increased clinical severity and resource use. This matters for inpatient reimbursement because the classification into this Diagnosis-Related Group adjusts payment upward to reflect higher expected costs of care.

DRG 199 Overview

DRG 199 covers inpatient cases of pneumothorax with Major Complication or Comorbidity related to the condition or its treatment, typically including spontaneous or traumatic lung collapse with severe physiological compromise or complex interventions. This Diagnosis-Related Group aggregates clinical severity to drive higher Medicare Severity Diagnosis-Related Group payments when a Major Complication or Comorbidity is present. It matters for Medicare payment because the presence of a Major Complication or Comorbidity increases the relative weight and therefore the hospital reimbursement for inpatient care. Clinical management, need for procedures such as chest tube insertion or surgery, and length of stay influence resource intensity under this Diagnosis-Related Group.

DRG 199 Overview

Acute interventional trials evaluating strategies for rapid pleural decompression and chest tube management in patients with pneumothorax complicated by major complications (MCC), such as hemodynamic instability or respiratory failure. These studies enroll hospitalized adults who present with primary or secondary pneumothorax plus serious physiologic compromise, and compare approaches like needle decompression timing, small-bore versus large-bore chest tubes, drainage protocols, and adjunctive measures to prevent persistent air leak. Findings are directly relevant to clinicians deciding immediate procedural care and to payers because optimized acute interventions can reduce ICU days, procedure-related complications, and overall inpatient costs associated with DRG 199 admissions.
Comparative effectiveness research comparing surgical and minimally invasive definitive treatments for recurrent or persistent pneumothorax in patients with severe comorbidity profiles. Trials in this area focus on subgroups such as patients with underlying chronic lung disease, advanced age, or coagulopathy who meet criteria for operative management versus prolonged conservative chest tube therapy; outcomes include recurrence, length of stay, complication rates, and resource use. This research informs guideline-based decisions about who benefits from operating-room–based interventions versus extended inpatient management, helping providers balance clinical benefit against the higher upfront costs that affect reimbursement under this DRG.
Post-discharge and health-services studies examining readmissions, long-term pulmonary function, and care transitions for survivors of pneumothorax with MCC. These cohort or pragmatic trials evaluate discharge timing, outpatient follow-up strategies, home nursing or telemonitoring for chest tube management, and rehabilitation needs, targeting patients discharged after complex inpatient courses with high risk of recurrent events or readmission. Results help payers and health systems design post-acute care pathways that reduce costly readmissions and downstream utilization while improving patient outcomes and functional recovery after an episode coded to DRG 199.

Acute interventional trials evaluating strategies for rapid pleural decompression and chest tube management in patients with pneumothorax complicated by major complications (MCC), such as hemodynamic instability or respiratory failure. These studies enroll hospitalized adults who present with primary or secondary pneumothorax plus serious physiologic compromise, and compare approaches like needle decompression timing, small-bore versus large-bore chest tubes, drainage protocols, and adjunctive measures to prevent persistent air leak. Findings are directly relevant to clinicians deciding immediate procedural care and to payers because optimized acute interventions can reduce ICU days, procedure-related complications, and overall inpatient costs associated with DRG 199 admissions.
Comparative effectiveness research comparing surgical and minimally invasive definitive treatments for recurrent or persistent pneumothorax in patients with severe comorbidity profiles. Trials in this area focus on subgroups such as patients with underlying chronic lung disease, advanced age, or coagulopathy who meet criteria for operative management versus prolonged conservative chest tube therapy; outcomes include recurrence, length of stay, complication rates, and resource use. This research informs guideline-based decisions about who benefits from operating-room–based interventions versus extended inpatient management, helping providers balance clinical benefit against the higher upfront costs that affect reimbursement under this DRG.
Post-discharge and health-services studies examining readmissions, long-term pulmonary function, and care transitions for survivors of pneumothorax with MCC. These cohort or pragmatic trials evaluate discharge timing, outpatient follow-up strategies, home nursing or telemonitoring for chest tube management, and rehabilitation needs, targeting patients discharged after complex inpatient courses with high risk of recurrent events or readmission. Results help payers and health systems design post-acute care pathways that reduce costly readmissions and downstream utilization while improving patient outcomes and functional recovery after an episode coded to DRG 199.

Pneumothorax with Major Complication or Comorbidity: Inpatient Reimbursement Overview

Sign up for drg 199 policy alerts

DRG 199 Overview

Pneumothorax with Major Complication or Comorbidity: Inpatient Reimbursement Overview

Sign up for drg 199 policy alerts

DRG 199 Overview

Clinical Trials

Related Codes

References

Clinical Trials

Related Codes

References